DE LAURENTIIS, MICHELINO
DE LAURENTIIS, MICHELINO
DIPARTIMENTO DI MEDICINA CLINICA E CHIRURGIA
Survival Analysis by means of a novel Neural Network Model
2003 Eleuteri, A; Tagliaferri, R; DE PLACIDO, Sabino; DE LAURENTIIS, Michelino
EXPRESSION OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) CORRELATES WITH DISEASE RELAPSE AND PROGRESSION TO ANDROGEN-INDEPEDENCE IN HUMAN PROSTATE CANCER.
2002 DI LORENZO, G; Tortora, G; D'Armiento, FRANCESCO PAOLO; DE ROSA, G; Staibano, Stefania; Autorino, R; D'Armiento, Maria; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Catalano, G; Bianco, Ar; Ciardiello, F.
Mitoxantrone, etoposide and bleomycin (MEB) chemotherapy in non-Hodgkin's Lymphoma patients non-elegible for standard cyclophosphamide, doxorubicin vincristine and prednisone (CHOP) combination.
1995 P., Tagliaferri; Matano, Elide; A., Rea; M., Famiani; F., Ciardiello; G., Tortora; V., Montesarchio; A., Morabito; M., Caraglia; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Palmieri, Giovannella; A. R., Bianco
Phase I-II study of xelox and bevacizumab plus erlotinib in sequential combination (XELOX-TARAV) in first line colorectal cancer: run in part
2007 G., Tortora; Carlomagno, Chiara; Bianco, Roberto; Daniele, G; Pepe, S; Leopardo, D; Marciano, Roberta; DE LAURENTIIS, Michelino; F., Ciardiello; DE PLACIDO, Sabino
Targeted Therapy of Breast Cancer
2009 DE LAURENTIIS, Michelino; Zielinski, C.
Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study.
2012 Nuzzo, F; Gallo, C; Lastoria, S; Di Maio, M; Piccirillo, Mc; Gravina, A; Landi, G; Rossi, E; Pacilio, C; Labonia, V; Di Rella, F; Bartiromo, A; Buonfanti, G; De Feo, G; Esposito, G; D'Aniello, R; Maiolino, Paola; Signoriello, S; De Maio, E; Tinessa, V; Colantuoni, G; DE LAURENTIIS, Michelino; D'Aiuto, M; Di Bonito, M; Botti, G; Giordano, P; Daniele, G; Morabito, A; Normanno, N; de Matteis, A; Perrone, F.
Lapatinib in breast cancer: clinical experiences and future perspectives.
2010 Giampaglia, M; Chiuri, Ve; Tinelli, A; DE LAURENTIIS, Michelino; Silvestris, N; Lorusso, V.
Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials.
2011 Mcgale, P; Correa, C; Taylor, C; Arriagada, R; Clarke, M; Cutter, D; Davies, C; Ewertz, M; Godwin, J; Gray, R; Pierce, L; Whelan, T; Wang, Y; Peto, R; Early Breast Cancer Trialists' Collaborative, Group; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Carlomagno, Chiara
Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials.
2007 Cuzick, J; Ambroisine, L; Davidson, N; Jakesz, R; Kaufmann, M; Regan, M; Sainsbury, R; LHRH agonists in Early Breast Cancer Overview, Group; DE LAURENTIIS, Michelino
Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment.
2011 Giuliano, Mario; Giordano, A; Jackson, S; Hess, Kr; De Giorgi, U; Mego, M; Handy, Bc; Ueno, Nt; Alvarez, Rh; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Valero, V; Hortobagyi, Gn; Reuben, Jm; Cristofanilli, M.
A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer.
2005 DE PLACIDO, Sabino; DE LAURENTIIS, Michelino; DE LENA, M; Lorusso, V; Paradiso, A; D'Aprile, M; Pistillucci, G; Farris, A; Sarobba, Mg; Palazzo, S; Manzione, L; Adamo, V; Palmeri, S; Ferrau, F; Lauria, Rossella; Pagliarulo, C; Petrella, Giuseppe; Limite, Gennaro; Costanzo, Raffaele; Bianco, Ar; GOCSI COOPERATIVE, G. R. O. U. P.
Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer.
2003 DE PLACIDO, Sabino; DE LAURENTIIS, Michelino; Carlomagno, C; Gallo, C; Perrone, F; Pepe, S; Ruggiero, A; Marinelli, Alfredo; Pagliarulo, C; Panico, L; Pettinato, ; Petrella, G; Bianco, Ar
Measurement of neovascularization is an independent prognosticator of survival in node-negative breast cancer patients with long-term follow-up.
1999 DE PLACIDO, Sabino; Carlomagno, C.; Ciardiello, F.; DE LAURENTIIS, Michelino; Pepe, S.; Ruggiero, A.; Tortora, G.; Panico, L.; D'Antonio, A.; Pettinato, G.; Petrella, G.; Bianco, A. R.
High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in Luminal B HER2 negative and node-positive breast cancer.
2014 Criscitiello, C; Disalvatore, D; DE LAURENTIIS, Michelino; Gelao, L; Fumagalli, L; Locatelli, M; Bagnardi, V; Rotmensz, N; Esposito, A; Minchella, I; DE PLACIDO, Sabino; Santangelo, Michele; Viale, G; Goldhirsch, A; Curigliano, G.
A technique for using neural network analysis to perform survival analysis of censored data.
1994 DE LAURENTIIS, Michelino; P. M., Ravdin
Taxanes and gemcitabine doublets in the management of HER-2 negative metastatic breast cancer: towards optimization of association and schedule.
2008 Metro, G.; Fabi, A.; Russillo, M.; Papaldo, P.; DE LAURENTIIS, Michelino; Ferretti, G.; Pellegrini, D.; Nuzzo, C.; Graziano, V.; Vici, P.; Introna, M.; Felici, A.; Cognetti, F.; Carlini, P.
Prognostic factors: rationale and methods of analysis and integration.
1994 G. M., Clark; S. G., Hilsenbeck; P. M., Ravdin; DE LAURENTIIS, Michelino; C. K., Osborne
c-erbB2 expression predicts tamoxifen efficacy in breast cancer patients.
1998 DE PLACIDO, Sabino; Carlomagno, C.; DE LAURENTIIS, Michelino; Bianco, A. R.
Effect of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
2005 Abe, O; Abe, R; Carlomagno, Chiara; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino
Central nervous system metastases in a cohort of metastatic breast cancer patients treated with trastuzumab.
2009 E., Montagna; G., Cancello; D., D'Agostino; Lauria, Rossella; Forestieri, Valeria; A., Esposito; L., Silvestro; Accurso, Antonello; DE PLACIDO, Sabino; DE LAURENTIIS, Michelino
| Titolo | Tipologia | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|---|
| Survival Analysis by means of a novel Neural Network Model | 1.1 Articolo in rivista | 2003 | Eleuteri, A; Tagliaferri, R; DE PLACIDO, Sabino; DE LAURENTIIS, Michelino | |
| EXPRESSION OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) CORRELATES WITH DISEASE RELAPSE AND PROGRESSION TO ANDROGEN-INDEPEDENCE IN HUMAN PROSTATE CANCER. | 1.1 Articolo in rivista | 2002 | DI LORENZO, G; Tortora, G; D'Armiento, FRANCESCO PAOLO; DE ROSA, G; Staibano, Stefania; Autorino, R; D'Armiento, Maria; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Catalano, G; Bianco, Ar; Ciardiello, F. | |
| Mitoxantrone, etoposide and bleomycin (MEB) chemotherapy in non-Hodgkin's Lymphoma patients non-elegible for standard cyclophosphamide, doxorubicin vincristine and prednisone (CHOP) combination. | 1.1 Articolo in rivista | 1995 | P., Tagliaferri; Matano, Elide; A., Rea; M., Famiani; F., Ciardiello; G., Tortora; V., Montesarchio; A., Morabito; M., Caraglia; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Palmieri, Giovannella; A. R., Bianco | |
| Phase I-II study of xelox and bevacizumab plus erlotinib in sequential combination (XELOX-TARAV) in first line colorectal cancer: run in part | 1.5 Abstract in rivista | 2007 | G., Tortora; Carlomagno, Chiara; Bianco, Roberto; Daniele, G; Pepe, S; Leopardo, D; Marciano, Roberta; DE LAURENTIIS, Michelino; F., Ciardiello; DE PLACIDO, Sabino | |
| Targeted Therapy of Breast Cancer | 8.01 Chairman di Sessioni di Convegni Internazionali | 2009 | DE LAURENTIIS, Michelino; Zielinski, C. | |
| Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study. | 1.1 Articolo in rivista | 2012 | Nuzzo, F; Gallo, C; Lastoria, S; Di Maio, M; Piccirillo, Mc; Gravina, A; Landi, G; Rossi, E; Pacilio, C; Labonia, V; Di Rella, F; Bartiromo, A; Buonfanti, G; De Feo, G; Esposito, G; D'Aniello, R; Maiolino, Paola; Signoriello, S; De Maio, E; Tinessa, V; Colantuoni, G; DE LAURENTIIS, Michelino; D'Aiuto, M; Di Bonito, M; Botti, G; Giordano, P; Daniele, G; Morabito, A; Normanno, N; de Matteis, A; Perrone, F. | |
| Lapatinib in breast cancer: clinical experiences and future perspectives. | 1.1 Articolo in rivista | 2010 | Giampaglia, M; Chiuri, Ve; Tinelli, A; DE LAURENTIIS, Michelino; Silvestris, N; Lorusso, V. | |
| Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. | 1.1 Articolo in rivista | 2011 | Mcgale, P; Correa, C; Taylor, C; Arriagada, R; Clarke, M; Cutter, D; Davies, C; Ewertz, M; Godwin, J; Gray, R; Pierce, L; Whelan, T; Wang, Y; Peto, R; Early Breast Cancer Trialists' Collaborative, Group; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Carlomagno, Chiara | |
| Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. | 1.1 Articolo in rivista | 2007 | Cuzick, J; Ambroisine, L; Davidson, N; Jakesz, R; Kaufmann, M; Regan, M; Sainsbury, R; LHRH agonists in Early Breast Cancer Overview, Group; DE LAURENTIIS, Michelino | |
| Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. | 1.1 Articolo in rivista | 2011 | Giuliano, Mario; Giordano, A; Jackson, S; Hess, Kr; De Giorgi, U; Mego, M; Handy, Bc; Ueno, Nt; Alvarez, Rh; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Valero, V; Hortobagyi, Gn; Reuben, Jm; Cristofanilli, M. | |
| A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer. | 1.1 Articolo in rivista | 2005 | DE PLACIDO, Sabino; DE LAURENTIIS, Michelino; DE LENA, M; Lorusso, V; Paradiso, A; D'Aprile, M; Pistillucci, G; Farris, A; Sarobba, Mg; Palazzo, S; Manzione, L; Adamo, V; Palmeri, S; Ferrau, F; Lauria, Rossella; Pagliarulo, C; Petrella, Giuseppe; Limite, Gennaro; Costanzo, Raffaele; Bianco, Ar; GOCSI COOPERATIVE, G. R. O. U. P. | |
| Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer. | 1.1 Articolo in rivista | 2003 | DE PLACIDO, Sabino; DE LAURENTIIS, Michelino; Carlomagno, C; Gallo, C; Perrone, F; Pepe, S; Ruggiero, A; Marinelli, Alfredo; Pagliarulo, C; Panico, L; Pettinato, ; Petrella, G; Bianco, Ar | |
| Measurement of neovascularization is an independent prognosticator of survival in node-negative breast cancer patients with long-term follow-up. | 1.1 Articolo in rivista | 1999 | DE PLACIDO, Sabino; Carlomagno, C.; Ciardiello, F.; DE LAURENTIIS, Michelino; Pepe, S.; Ruggiero, A.; Tortora, G.; Panico, L.; D'Antonio, A.; Pettinato, G.; Petrella, G.; Bianco, A. R. | |
| High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in Luminal B HER2 negative and node-positive breast cancer. | 1.1 Articolo in rivista | 2014 | Criscitiello, C; Disalvatore, D; DE LAURENTIIS, Michelino; Gelao, L; Fumagalli, L; Locatelli, M; Bagnardi, V; Rotmensz, N; Esposito, A; Minchella, I; DE PLACIDO, Sabino; Santangelo, Michele; Viale, G; Goldhirsch, A; Curigliano, G. | |
| A technique for using neural network analysis to perform survival analysis of censored data. | 1.1 Articolo in rivista | 1994 | DE LAURENTIIS, Michelino; P. M., Ravdin | |
| Taxanes and gemcitabine doublets in the management of HER-2 negative metastatic breast cancer: towards optimization of association and schedule. | 1.1 Articolo in rivista | 2008 | Metro, G.; Fabi, A.; Russillo, M.; Papaldo, P.; DE LAURENTIIS, Michelino; Ferretti, G.; Pellegrini, D.; Nuzzo, C.; Graziano, V.; Vici, P.; Introna, M.; Felici, A.; Cognetti, F.; Carlini, P. | |
| Prognostic factors: rationale and methods of analysis and integration. | 1.1 Articolo in rivista | 1994 | G. M., Clark; S. G., Hilsenbeck; P. M., Ravdin; DE LAURENTIIS, Michelino; C. K., Osborne | |
| c-erbB2 expression predicts tamoxifen efficacy in breast cancer patients. | 1.1 Articolo in rivista | 1998 | DE PLACIDO, Sabino; Carlomagno, C.; DE LAURENTIIS, Michelino; Bianco, A. R. | |
| Effect of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials | 1.1 Articolo in rivista | 2005 | Abe, O; Abe, R; Carlomagno, Chiara; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino | |
| Central nervous system metastases in a cohort of metastatic breast cancer patients treated with trastuzumab. | 1.1 Articolo in rivista | 2009 | E., Montagna; G., Cancello; D., D'Agostino; Lauria, Rossella; Forestieri, Valeria; A., Esposito; L., Silvestro; Accurso, Antonello; DE PLACIDO, Sabino; DE LAURENTIIS, Michelino |